Journal of Clinical & Experimental Pharmacology

Challenges and opportunities: Entwined twins of generic pharmaceutical formulation development

Co-organized Event International Conference on Toxicology and Clinical Pharmacology & 2^nd International Conference on Generic Drugs and Biosimilars

December 14-16, 2017 Rome, Italy

Atul Pathak

BioVectra Inc., Canada

Posters & Accepted Abstracts: Clin Exp Pharmacol

Abstract:

As pharmaceutical industry has increasingly shifted their focus to therapeutic segments like oncology, biologics have become a larger component of the industryâ??s development pipeline. Further, novel drug delivery systems have had an enormous impact on medical technology, greatly improving the performance of many existing drugs and enabling the use of entirely new therapies. These two factors, among others, have led to a rapid growth in the sterile injectable technologies and formulationsâ?? market. The global sterile injectable market is projected to reach >$400 billion by 2018. The generic sterile injectable market is expected to grow at a 10% annual rate, driving the overall injectable market up 6% annually through 2020. The sterile injectables formulation technologies market can be segmented into conventional and novel formulations. The conventional dosage forms can be further categorized into solutions and lyophilized / water for reconstitution. Novel drug delivery formulations (i.e. depot formulations and liposomal drug carriers) have gained prominence in the last few years for enhanced disease targeting and to increase patient compliance and considered as complex generic in industry.